Published in Gynecol Oncol on July 01, 1999
RhoBTB2 is a substrate of the mammalian Cul3 ubiquitin ligase complex. Genes Dev (2004) 1.60
Laser capture microdissection in pathology. J Clin Pathol (2000) 1.50
PDLIM2 suppresses human T-cell leukemia virus type I Tax-mediated tumorigenesis by targeting Tax into the nuclear matrix for proteasomal degradation. Blood (2009) 1.36
Mystique is a new insulin-like growth factor-I-regulated PDZ-LIM domain protein that promotes cell attachment and migration and suppresses Anchorage-independent growth. Mol Biol Cell (2005) 1.36
Improvement of tissue preparation for laser capture microdissection: application for cell type-specific miRNA expression profiling in colorectal tumors. BMC Genomics (2010) 1.09
NF-κB and cancer: a paradigm of Yin-Yang. Am J Cancer Res (2010) 1.08
High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer. Br J Cancer (2001) 0.96
Genomic organization of human arylamine N-acetyltransferase Type I reveals alternative promoters that generate different 5'-UTR splice variants with altered translational activities. Biochem J (2005) 0.90
Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer. Br J Cancer (2003) 0.87
RhoBTB2 (DBC2) is a mitotic E2F1 target gene with a novel role in apoptosis. J Biol Chem (2007) 0.83
Hsp90-dependent assembly of the DBC2/RhoBTB2-Cullin3 E3-ligase complex. PLoS One (2014) 0.79
The microenvironment of the tumour-host interface. Nature (2001) 9.17
Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science (1997) 7.95
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med (1996) 7.09
Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene (2001) 4.40
Laser capture microdissection: molecular analysis of tissue. Science (1997) 3.93
High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer (2004) 3.75
Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A (1997) 3.27
The cancer genome anatomy project: building an annotated gene index. Trends Genet (2000) 3.02
BRCA2 mutations in primary breast and ovarian cancers. Nat Genet (1996) 2.91
PTEN/MMAC1 mutations in endometrial cancers. Cancer Res (1997) 2.89
Laser-capture microdissection: opening the microscopic frontier to molecular analysis. Trends Genet (1998) 2.60
Immuno-LCM: laser capture microdissection of immunostained frozen sections for mRNA analysis. Am J Pathol (1999) 2.59
A microdissection technique for archival DNA analysis of specific cell populations in lesions < 1 mm in size. Am J Pathol (1995) 2.59
A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci U S A (2001) 2.57
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene (2008) 2.47
Recommendations for sentinel lymph node processing in breast cancer. Am J Surg Pathol (2002) 2.42
Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst (1997) 2.30
Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ (1990) 2.24
Genetic instability of microsatellites in endometrial carcinoma. Cancer Res (1993) 2.20
Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res (1991) 2.20
Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol (1995) 2.02
Cost-effectiveness of treatment of early stage endometrial cancer. Gynecol Oncol (1999) 1.99
Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet (1997) 1.90
Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res (1995) 1.85
Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res (1997) 1.82
A transcript map for the 2.8-Mb region containing the multiple endocrine neoplasia type 1 locus. Genome Res (1997) 1.82
Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci U S A (2001) 1.82
Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst (1998) 1.81
Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet (1994) 1.81
An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res (2000) 1.81
Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res (1996) 1.78
Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet (1997) 1.77
von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol (1997) 1.74
Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst (1993) 1.71
Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet (1997) 1.70
Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst (1993) 1.60
p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol (1996) 1.59
The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol (1990) 1.59
PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res (1998) 1.58
Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer. Cancer Res (1995) 1.57
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol (2013) 1.55
Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br J Cancer (2009) 1.54
Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res (2000) 1.50
Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor. Gynecol Oncol (2001) 1.48
Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res (1998) 1.46
BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. Cell Growth Differ (1996) 1.45
Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Hum Pathol (1994) 1.45
A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol (1993) 1.44
The role of partial sigmoid colectomy for debulking epithelial ovarian carcinoma. Gynecol Oncol (1991) 1.42
Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ (1994) 1.42
Loss of heterozygosity on chromosome 13 is associated with advanced stage prostate cancer. J Urol (1999) 1.41
Mutational analysis of the PTEN gene in human uterine sarcomas. Am J Obstet Gynecol (2001) 1.41
Electrophoretic karyotype for Dictyostelium discoideum. Proc Natl Acad Sci U S A (1990) 1.40
Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J Natl Cancer Inst (1994) 1.39
Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am J Pathol (1994) 1.38
Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. Br J Cancer (2008) 1.38
Necropsy as a research method in the age of molecular pathology. Lancet (1995) 1.37
Cell cycle control of BRCA2. Cancer Res (1996) 1.32
Mutations of the MEN1 tumor suppressor gene in pituitary tumors. Cancer Res (1997) 1.31
Clinical proteomics: personalized molecular medicine. JAMA (2001) 1.30
Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. Recent Prog Horm Res (1999) 1.29
Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair. Nat Genet (1996) 1.28
Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol (1995) 1.27
Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol Carcinog (1996) 1.27
Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res (1993) 1.26
The genetics of cancer--a 3D model. Nat Genet (1999) 1.26
Layered expression scanning: rapid molecular profiling of tumor samples. Cancer Res (2000) 1.24
Construction of a representative cDNA library from prostatic intraepithelial neoplasia. Cancer Res (1996) 1.23
Loss of heterozygosity at 11q13: analysis of pituitary tumors, lung carcinoids, lipomas, and other uncommon tumors in subjects with familial multiple endocrine neoplasia type 1. J Clin Endocrinol Metab (1997) 1.23
Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer (2006) 1.23
Allelic loss in esophageal squamous cell carcinoma patients with and without family history of upper gastrointestinal tract cancer. Clin Cancer Res (1999) 1.20
Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC). J Intern Med (2012) 1.20
Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. Br J Cancer (2009) 1.19
The biochemistry of cancer dissemination. Crit Rev Biochem Mol Biol (1997) 1.19
Identification of novel regions of allelic loss from a genomewide scan of esophageal squamous-cell carcinoma in a high-risk Chinese population. Genes Chromosomes Cancer (2000) 1.19
Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis (2000) 1.18
Genetic analysis of synchronous mucinous tumors of the ovary and appendix. Hum Pathol (1996) 1.17
Development of a prostate cDNA microarray and statistical gene expression analysis package. Mol Carcinog (2000) 1.16
Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol (1993) 1.16
Gestational trophoblastic disease metastatic to the central nervous system. Gynecol Oncol (1995) 1.15
Frequent inactivation of the TP53 gene in esophageal squamous cell carcinoma from a high-risk population in China. Clin Cancer Res (2001) 1.14
Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst (1992) 1.13
An improved method for construction of directionally cloned cDNA libraries from microdissected cells. Cancer Res (1998) 1.13
Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res (1993) 1.13
A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus. Cancer Res (1993) 1.12
p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem (1992) 1.12
Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res (1992) 1.11
Metastases to breast simulating ductal carcinoma in situ: report of two cases and review of the literature. Ann Diagn Pathol (2001) 1.11
Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Cancer Res (1997) 1.10
The multiple endocrine neoplasia type I gene locus is involved in the pathogenesis of type II gastric carcinoids. Gastroenterology (1997) 1.10
Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1-associated and sporadic gastrinomas and pancreatic endocrine tumors. Cancer Res (1997) 1.08
Relationship between race and interval to treatment in endometrial cancer. Obstet Gynecol (1995) 1.08
Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol (1996) 1.08